Jane Street Group LLC Cuts Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Jane Street Group LLC cut its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 56.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 84,652 shares of the company's stock after selling 108,141 shares during the period. Jane Street Group LLC owned approximately 0.16% of Voyager Therapeutics worth $495,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in VYGR. Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock worth $41,132,000 after buying an additional 528,000 shares during the period. Great Point Partners LLC purchased a new position in shares of Voyager Therapeutics in the second quarter valued at about $12,668,000. Erste Asset Management GmbH bought a new position in shares of Voyager Therapeutics during the third quarter valued at about $6,192,000. American Century Companies Inc. raised its stake in shares of Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock valued at $8,063,000 after acquiring an additional 249,659 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company's stock worth $4,384,000 after purchasing an additional 2,638 shares during the period. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.53% of the stock is owned by company insiders.

Voyager Therapeutics Stock Down 0.3 %

Shares of NASDAQ:VYGR traded down $0.02 during midday trading on Monday, reaching $6.02. The company's stock had a trading volume of 481,757 shares, compared to its average volume of 408,986. The firm has a 50 day moving average of $6.19 and a 200-day moving average of $6.87. The firm has a market capitalization of $328.85 million, a P/E ratio of 8.48 and a beta of 0.93. Voyager Therapeutics, Inc. has a 12-month low of $5.19 and a 12-month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the firm earned ($0.59) earnings per share. On average, research analysts predict that Voyager Therapeutics, Inc. will post -0.89 EPS for the current year.

Analyst Ratings Changes

VYGR has been the topic of a number of research analyst reports. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price target on the stock. Wedbush assumed coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an "outperform" rating and a $11.00 target price for the company. StockNews.com cut shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a "buy" rating and a $12.00 price objective for the company. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $17.43.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.